Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2019 Sep 23;19(1):221–230. doi: 10.1158/1535-7163.MCT-19-0103

Figure 5.

Figure 5.

Targeting Nrf2/GSH axis suppresses IDH1-mutated xenografts

A. Schematic illustration for the xenograft and treatment schedule.

B. Tumor growth curve of TS603 xenografts. n=10 for each group. **p<0.01.

C. Gross anatomy of TS603 xenografts.

D. Immunohistochemistry assay showed the expression of Ki67, γH2A.X and TUNEL assay in tumor sections. Bar = 50 μm.

E. Immunohistochemistry assay showed the expression of Nrf2, SLC7A11, GCLC and GCLM in tumor sections. Bar = 50 μm.